

## PROMETHEUS® Thiopurine Metabolites Cat. # 3200

### Product Description

PROMETHEUS® Thiopurine Metabolites testing assists physicians in optimizing ongoing dosing of thiopurine immunosuppressant therapy to reach and maintain therapeutic goal. Thiopurine metabolite testing also helps to identify drug metabolite levels that may lead to toxicity and some of the reasons for treatment failure.

- A quantitative evaluation of 6-TGN (thioguanine nucleotide) and 6-MMPN (methyl mercaptopurine nucleotide)
- PROMETHEUS Thiopurine Metabolites is only offered at Prometheus.
- Patent protected.
- **Specimen Requirements** - Whole blood, 5.0 mL; EDTA / Lavender Top Tube.
- **Shipping and Handling** - Refrigerate; Ship with cold pack (DO NOT FREEZE).
- **Storage Conditions/Stability** - 8 days refrigerated; 24 hours ambient.
- **Turn Around Time** - 3 business days from date of receipt.
- **Therapeutic Range** - 6-TGN: 235-400 pmole/8X10<sup>8</sup> RBC; 6-MMPN: <5,700 pmole/8X10<sup>8</sup> RBC.

### Facilities Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- Prometheus Laboratories Inc. is CLIA certified and accredited by the College of American Pathologists. This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration.

### CPT Codes (as applied by Prometheus)

- **82491(X2)**, Quantitative HPLC (High Pressure Liquid Chromatography) for each nucleotide in peripheral RBC, separate stationary and mobile phase.

### Literature References

- Dubinsky MC, Reyes E, Ofman J, et al. A cost-effective analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Am J Gastroenterol.* 2005;100(10):2239-2247.
- Seidman EG, Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. *Rev Gastroenterol Disord.* 2003;3(suppl 1):S30-S38.
- Cuffari C, et al. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. *Gut.* 2001;48:642-646.
- Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. *Gastroenterology.* 2000;118:705-713.